Effects of Sancai Lianmei Granules in type 2 diabetes patients with metabolic dysfunction-associated fatty liver disease: a randomized prospective open-label controlled trial
Shengju Wang, Yuguo Xia, Xuke Han, Yang Gao, Xiaoran Zhang, Xingxing Lei, Xu Zhang, Qiu Chen · 2025
Read Effects of Sancai Lianmei Granules in type 2 diabetes patients with metabolic dysfunction-associated fatty liver disease: a randomized prospective open-label controlled trial by Shengju Wang, Yuguo Xia, Xuke Han, Yang Gao, Xiaoran Zhang, Xingxing Lei, Xu Zhang, Qiu Chen (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12729198.txt.
Description
Shengju Wang and co-authors run a trial of herbal granules for patients who have both type 2 diabetes and fatty liver disease, in work from 2025. The granules had already shown gains for blood sugar, blood fats, and insulin response in people and rodents. Human liver data were missing.
Sixty patients were split at random. One group got standard diabetes care plus the granules three times a day; the other got standard care alone, for twelve weeks. A scan method gauged liver fat and stiffness. Blood tests tracked liver enzymes, scarring markers, sugar byproducts, and metabolism. The granule group improved beyond standard care on the measured fronts, the report finds.
Catalog record
| CREATOR | Shengju Wang, Yuguo Xia, Xuke Han, Yang Gao, Xiaoran Zhang, Xingxing Lei, Xu Zhang, Qiu Chen |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 35 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |